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The pharmacokinetics (PK) of ordinary tablets and sustained release capsules of diltiazem hydrochloride 
in human clinical trials had been studied. The PK of diltiazem hydrochloride delay-onset sustained-release 
pellet capsules, a new dosage form, has not been reported, although it is very important to clinical use. In 
this paper, we investigated the PK of diltiazem hydrochloride delay-onset sustained-release pellet capsules 
and the food influence in Chinese healthy volunteers. The PK parameters indicated that the diltiazem 
hydrochloride delay-onset sustained-release pellet capsules appeared marked characteristics of delayed and 
controlled release. An opened-label, randomized and parallel clinical trial was conducted in 36 Chinese 
healthy volunteers with single oral dose (90 mg, 180 mg or 270 mg) and a multiple oral dose (90 mg d-1×6 d) 
administration. The effect of food on the PK of one single oral dose (360 mg) was investigated in 24 healthy 
Chinese volunteers. Plasma diltiazem concentration was determined by reversed-phase high-performance 
liquid chromatography (RP-HPLC) and the main pharmacokinetic parameters were analyzed by PKSolver 
(Ver 2.0). All clinical studies were conducted in the Clinical Pharmacological Center (No. JDX1999064) 
of Xiangya Hospital Affiliated Central South University, China. The PK parameters suggested that the new 
formulation had marked characteristics of delayed and controlled release of diltiazem, and food intake did 
not alter significantly diltiazem pharmacokinetic parameters.
Uniterms: Diltiazem hydrochloride/delay-onset sustained-release pellet capsules/pharmacokinetics. 
Food/ingestion/effect in pharmacokinetic profile. High-performance liquid chromatography/quantitative 
analysis.
Embora a farmacocinética (PK) do cloridrato de diltiazem nas formas de comprimidos de liberação imediata 
e cápsulas de liberação modificada em ensaios clínicos já tenha sido relatada, a pesquisa da PK do cloridrato 
de diltiazem na forma de cápsulas com peletes de liberação retardada e sustentada ainda é muito importante. 
Neste trabalho, propusemos avaliar a farmacocinética do cloridrato de diltiazem administrado através 
desta nova forma farmacêutica em voluntários chineses sadios, assim como a influência da ingestão de 
alimentos neste perfil farmacocinético. Foi realizado um ensaio clínico aberto, randomizado e paralelo em 36 
voluntários, que receberam dose oral única de 90 mg, 180 mg ou 270 mg e dose múltiplas (90 mg/d × 6 d) 
pela mesma via de administração. Para avaliar o efeito da ingestão de alimentos sobre a PK do diltiazem 
foi realizada a administração de dose única (360 mg) em 24 voluntários chineses sadios. A concentração 
plasmática do diltiazem foi determinada por Cromatografia Liquida de Alta Eficiência em fase reversa 
(CLAE-FR) e os principais parâmetros farmacocinéticos foram analisados através do emprego do software 
PKSolver (Ver 2.0). O ensaio de farmacocinética clínica foi conduzido na clínica Pharmacological Center 
(No.JDX1999064) do Hospital de Xiangya, Central South University, China. Os parâmetros PK obtidos 
indicaram que a nova formulação de cápsulas de liberação retardada e sustentada de cloridrato de diltiazem 
possue marcantes características de liberação retardada e controlada do fármaco.
Unitermos: Cloridrato de diltiazem/peletes de liberação retardada e sustentada/farmacocinética. 
Alimentos/ingestão/efeito no perfil famacocinético. Cromatografia Líquida de Alta Eficiência/análise 
quantitativa.
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INTRODUCTION
Diltiazem, a calcium channel blocker of the benzo-
diazepine family, has been widely used for the treatment 
of angina pectoris (Chaffman, Brogden, 1985; Théroux et 
al., 1985; Hossack et al., 1981) and hypertension (Zhang 
et al., 2010; Bertere et al., 2009; Färbom et al., 2008), 
especially treatment of the hypertension with angina 
pectoris (Ezeugo, Glasser, 2009; Claas, Glasser, 2005). 
Pharmacodynamic studies showed that diltiazem might 
affect heart muscle by blocking influx of extracellular fluid 
calcium (Britt, 1985) and improving affinity of 1, 4-dihy-
dropyridines for the Ca2+ channel (Glossmann et al., 1980).
Diltiazem has been introduced into clinical practice 
as the ordinary tablets and delay-onset capsules. The 
patient has to take the drug three times a day because 
the effective plasma concentration of diltiazem sustains 
so short time after the administration (Hekmatara et al., 
2006; Mazzo et al., 1994). Although the sustained-release 
capsules of diltiazem hydrochloride keeps the diltiazem 
release and absorption slowly, the blood concentration is 
relatively low and flat, which is not suitable to the circa-
dian rhythm of blood pressure (Weir, 1995; Scholz, 1997). 
So the extended and controlled release diltiazem form is 
better for the clinical requirement.
As a new form, diltiazem hydrochloride delay-onset 
sustained-release pellet is prepared by spraying diltiazem 
solution onto the surface of celpheres and then coating 
with hydroxy propyl methyl cellulose as swelling layer 
and Surelease as coating layer (Dey et al., 2008). There 
are two pellet kinds depending on adjusting the proportion 
of the surface macromolecular layer: one is a rapid release 
pellet after a long certain delayed time, and the other is an 
extended release pellet after a long certain delayed time. 
The two pellet kinds that are loaded in one single capsule 
ensure to delay the release of the active ingredient ef-
fecting in sufficient amount and extend for enough time. 
The delayed drug release is compatible with the chrono-
pharmacologic drug delivery systems (Smolensky et al., 
2007). These capsules delay the release of diltiazem for 
4-6 h and be effectively compatible with the circadian 
variation of the disease.
The pharmacokinetics (PK) of ordinary tablets and 
sustained capsules of diltiazem hydrochloride in human 
trials were already studied (Yeung et al., 1999; Sista et al., 
2003; Caillé et al., 1991; Weiner et al., 1986). The PK of 
diltiazem hydrochloride delay-onset sustained-release pel-
let capsules with the delayed and controlled drug release is 
very important for this new medicine, although it has not 
been reported. The aim of the present work was to evaluate 
the PK of diltiazem hydrochloride delay-onset sustained-
release pellet capsules and the influence of food on drug 
absorption in Chinese healthy volunteers, via establishing 
an analytical method to quantify human plasma diltiazem 
concentration by reversed-phase high-performance liquid 
chromatography (RP-HPLC).
MATERIAL AND METHODS
Drug and reagents
Four dosages (90 mg, 180 mg, 270 mg and 360 mg) 
of diltiazem hydrochloride delay-onset sustained-release 
pellet capsules (Batch: 111202, Specifications: 90 mg/
capsule) for single, multiple and food-effect oral admin-
istrations were made. Each capsule was contained of 
two kinds of pellets consisted of HPMC and Surelease, 
in which one was the short delayed release and the other 
was the long delayed release, respectively. Diltiazem hy-
drochloride reference substance (Batch: 070223-201101) 
was purchased from Chinese National Institutes for Food 
and Drug Control with the purity of diltiazem more than 
98.4%. Alprazolam reference substance (Batch: 0912) was 
obtained from State Narcotics Laboratory, China, with 
the purity of alprazolam more than 99.8%. Acetonitrile 
(HPLC grade) was purchased from Caledon Company, 
Canada. Double Distilled water and other reagents were 
analytical grade.
Instruments
The HPLC system was an Agilent Chemistation 
Rev.A.08.03 System (HPLC1100, Agilent, American) 
equipped with a G1313A quaternary pump, a vacuum de-
gasser, a G-1316 column oven, and a G1315B photodiode 
array detector. Low speed centrifuge (80-20) was from 
Shanghai Medical Instrument Co., Ltd. (Shanghai, China).
Test subjects
Thirty six Chinese volunteer, half male and half 
female, with mean age of 23.4 ± 3.7 (18-27 years), mean 
weight of 64.5 ± 5.8 kg with body mass index (BMI) 
23.4-24.6 kg m-2, and mean height of 167.0 ± 5.8 cm were 
enrolled in the study. All the subjects were confirmed to 
be healthy by physical examination, passing through the 
clinical laboratory tests, and screening the medical his-
tories. None of the subjects had any surgery or took any 
alterative medications other than diltiazem hydrochloride. 
No medications were taken for at least two weeks before 
the study. Tobacco, alcohol, beverage containing alcohol 
and caffeine were forbidden 48 h before the study and 
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during the study. During process of the single and multiple 
dose clinical studies, all subjects were fed with the uni-
fied light foods diet and confined in special wards. In the 
food-effect study, the high fat food diet used was based on 
the Guideline Recommendation of US FDA but adopted 
to Chinese dietary habit include: one fried egg, pork (fat: 
lean=2:1) 75 g, rape 100 g, colza oil 20 ml for cooking, 
the steamed bread 100 g and rice gruel 150 mL as staple 
food. The above Chinese food could provide approxi-
mately 1118 calories. Following the Guidance of Helsinki 
Declaration, all subjects signed the informed consent. 
The study protocol was approved by Ethic Committee 
of Xiangya Hospital Affiliated Central South University, 
China (Protocol JDX1999064).
Study design
Single dose study
An opened-label, randomized, parallel and single 
dose clinical study was carried out in 36 Chinese healthy 
volunteers. The subjects were equally (12 subjects one 
group, male and female equalization) divided to three 
groups as A, B, and C, and were administrated with speci-
fied doses of 90, 180 and 270 mg diltiazem respectively. 
All subjects were supplied with unified light diet, and then 
fasted but water supplied overnight before the drug admin-
istration and given corresponding diltiazem hydrochloride 
delay-onset sustained-release pellet capsules (Group A, 1 
capsule; Group B, 2 capsules, Group C, 3 capsules) with 
240 mL warm water for oral administration. And food was 
withheld for an additional 4 hours. Venous blood (5 ml) 
for pharmacokinetics study was collected into the hepa-
rinized tubes before drug administration (0 hour) and at 
0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, and 36 h 
after drug oral administration. The blood was immediately 
centrifuged for 10 min at 3000 rpm·min-1 to separate the 
plasma, which then was frozen and stored at -40 °C for 
assay. Adverse events of each subject were carefully ob-
served and recorded during the study.
Multiple dose study
Multiple dose studies were carried out in Group A 
(12 volunteers) 14 days after the single dose study when 
the wash-out period passed. All subjects were fasted but 
water supplied overnight before each drug administration, 
and then given corresponding diltiazem hydrochloride 
delay-onset sustained-release pellet capsules (one capsule, 
90 mg) with 240 mL warm water at 8:00 in the next morn-
ing. It was continued the drug administration (one capsule) 
for 6 days. Venous blood (5 mL) for pharmacokinetics 
study was collected into the heparinized tubers before drug 
administration (0 hour) in the 4th, 5th, 6th day and after oral 
administration at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 
12, 24 and 36 h in the 6th day. The blood was immediately 
centrifuged for 10 min at 3000 r·min-1 to separate the 
plasma, which was frozen and stored at -40 °C for assay. 
Adverse events of each subject were carefully observed 
and recorded during the study.
Food-effect study
The effect of food on corresponding diltiazem hy-
drochloride delay-onset sustained-release pellet capsules 
was carried out in group B and C (24 volunteers) after the 
single dose study. A randomized, open-label, two-period 
crossover method was designed to take a single dose of 
diltiazem (360 mg, 4 capsules) with a 14 days wash-out 
period between the two occasions. Subjects were admitted 
to ward on the day before the drug administration. From 
7:00 pm after dinner to the dosing on the day, subjects were 
not allowed to eat any food expect water. Subjects were 
randomized to treat (the delay-onset sustained-release pel-
let capsules 360 mg without food (fasting condition), or 
with high-fat food (fed). After a 14-days washout period, 
subjects were crossed over to the alternate treatment. All 
subjects received the same lunch and supper following 
drug administration. After administration, the subjects in 
the fasted group remained fasting for 4 hours. Water was 
allowed ad libitum throughout the study period except for 
4 hours pre- and post-study drug administration. Strenu-
ous exercise was not permitted during the 36-hour post-
dose monitoring period. Blood (5 mL) was collected into 
heparinized tubes before and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 
6, 7, 8, 9, 10, 12, 24 and 36 hours after drug administra-
tion. The blood was immediately centrifuged for 10 min 
at 3000 r·min-1 to separate the plasma, which was frozen 
and stored at -40 °C for assay.
Analysis of blood samples
·	 Blood preparation
To 1 mL of spiked plasma sample, 30 μL of a 
solution containing alprazolam (2.44 μg.mL-1, inter-
nal standard) and 1 mL of sodium hydroxide solution 
(0.1 mol.L-1) were added, and then the obtained mixture 
was vortex-mixed for 1 min. An aliquot of the hexane: 
trichloromethane: isopropanol (60:40:5) (5 mL) was then 
added to the mixture, vortex-mixed for another 2 min and 
then centrifuged at 3000 rpm for 10 min. The supernatant 
was collected and evaporated to dryness under a nitro-
gen stream at -40 °C. The residues were reconstituted 
with 100 μL of the mobile phase, respectively, and an 
aliquot of 50 μL of each sample was injected to HPLC 
for LC-UV analysis.
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·	 RP-HPLC conditions
The blood was separated on Gemini ODS C18 
(4.6 mm×550 mm, 5 μm) column and detected at the UV 
wavelength of 215 nm. The HPLC separation temperature 
was set at 35 oC. The mobile phase was made up of aceto-
nitrile: 0.08% triethylamine solution 37: 63 (v/v) (adjusted 
to pH 3.01-3.06 using phosphoric acid) at a flow rate at 
1.2 mL·min-1. 
Method validation
·	 Calibration curve and limit of quantification
The RP-HPLC analytical method was validated by 
evaluated linearity of standard curve, intra-day and inter-
day precision and accuracy, and recovery of diltiazem 
extracted in plasma. The calibration curve was constructed 
using seven different concentration levels of diltiazem 
without 0. 
The limit of the quantification was defined as the 
lowest amount of the analyte in plasma that was quanti-
tatively determined with suitable precision (≤20%) of the 
true concentration.
·	 Recovery, accuracy and precision
To determine the absolute recovery of diltiazem in 
plasma, three different concentration levels at 10.1, 80.8, 
and 646.4 ng.mL-1 of diltiazem were obtained by spiked 
diltiazem into the blank plasma, in which the diltiazem 
level was so low that was difficult to be measured, with 
six replicates for each concentration, and then the samples 
were extracted and analyzed by the RP-HPLC as described 
above. The absolute recoveries of diltiazem were obtained 
by dividing peak areas of extracted samples by those of 
corresponding spiked standard solution in the extracted 
blank plasma.
Accuracy and precision of the method were assessed 
by intra-day and inter-day analysis of six replicates for 
each concentration at 3 different concentration levels (10.1, 
80.8, and 646.4 ng.mL-1, respectively). The coefficient of 
variation (CVs) at each concentration level was expressed 
as precision. The intra-day and inter-day precision was ana-
lyzed by one-way analysis of variance (ANOVA) method.
·	 Sample stability tests
The stability tests were to measure the concentra-
tions of the spiked diltiazem in the blank plasma which 
were placed on the laboratory desk at room temperature 
for 24 h, which were frozen and defrosted for 1 to 3 times, 
or which were stored at frozen condition for 0 to 28 days.
·	 Quality control samples
Diltiazem was spiked into the blank plasma to 
reach the final concentration levels at 10.1, 80.8, and 
646.4 ng.mL-1, respectively as quality control samples. The 
quality control concentrations should cover the concentra-
tions of the target analyses.
The data processing and statistical analysis
Plasma diltiazem concentration profiles of 36 sub-
jects were presented as mean ± standard deviation (SD). 
Main pharmacokinetics parameters were calculated for 
each subject. Tmax and Cmax were obtained directly from the 
observed data. Plasma concentrations that lower than the 
lower limit of quantification (LLOQ) were assigned as a 
value of zero for the calculation of plasma concentrations 
and pharmacokinetic parameters. All the PK parameters 
were calculated by the PK-Solver 2.0 (China Medicine 
University, China).
RESULTS
Method validation
Chromatographic behaviors
The typical chromatograms of diltiazem were shown 
in Figure 1. The analyte and Internal standard (IS) were 
separated very well, where the retention time of diltiazem 
and IS was at 6.8 min and 9.3 min, respectively. It was 
not found any endogenous interference peaks on their 
chromatograms.
Linearity of the calibration curve and the limit of 
quantification
The diltiazem was added into blank plasma to obtain 
the concentrations of standard solutions at 10.1, 20.2, 40.4, 
80.8, 161.6, 323.2 and 646.6 ng.mL-1. The samples were 
prepared and analyzed by RP-HPLC as above. A good lin-
ear correlations regression equation of diltiazem was fitted 
as: Y = (0.00586) X + 0.02481, r = 0.9990, (where X was 
the plasma concentration of diltiazem hydrochloride, and 
Y was the peak area ratio of IS diltiazem hydrochloride). 
The calibration curve linearity of diltiazem hydrochloride 
was from the range of 10.1 to 646.4 ng.mL-1.
Recovery, accuracy and precision
The absolute recoveries of diltiazem extracted in 
plasma were 82.9 ± 18.4, 94.6 ± 14.9 and 70.5 ± 7.1%, 
respectively, corresponding for the three concentration 
levels of 10.1, 80.8, and 646.4 ng.mL-1 listed in Table I. 
The recovery of IS was 97.2 ± 5.4 %. The absolute recov-
ery rates of this method were suitable for the PK studies 
of diltiazem in human plasma (Werghese et al., 1983).
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TABLE I - The recovery rates of diltiazem and internal standard
samples concentration (ng.mL-1)
peak area mean 
recovery 
(%)
RSD (%)A
B
1 2 3 4 5
diltiazem 10.1 14.3 12.2 11.4 11.7 17.3 16.2 82.9 18.4
80.8 118.4 117.1 84.9 91.4 96.6 107.5 94.6 14.9
646.4 657.5 621.5 713.8 679.3 596.9 927.5 70.5 7.1
alprazolam 2.44 153.6 169.9 160.2 169.3 176.2 170.7 97.2 5.4
The result of the peak area of the diltiazem dissolved in plasma was marked as A (repeated for five times); the peak area of diltiazem 
dissolved in mobile phase was marked as B.
FIGURE 1 - Typical HPLC chromatograms of diltiazem in 
plasma. A: chromatogram of blank plasma; B: chromatogram 
of the mixed standard diltiazem (0.1 μg/mL) (a) and alprazolam 
(0.1 μg/mL) (b); C: chromatogram of blank plasma spiked with 
diltiazem (0.1 μg/mL) (a) and alprazolam (0.1 μg/mL) (b); D: 
chromatogram of diltiazem (0.1 μg/mL) (a) plasma samples 
mixed with alprazolam (0.1 μg/mL) (b).
Table II was the precision and accuracy of intra-
day and inter-day. The results showed the precision of 
intra-day analysis of diltiazem spiked in the blank plasma 
at three different concentration levels were 6.2%, 5.6%, 
2.7%, respectively, and that of the inter-day were 7.3%, 
3.0% and 4.4%, respectively. These data demonstrated 
high precision and accuracy of the method.
Sample stability
·	 Stability of plasma diltiazem at room temperature
The blank plasma with diltiazem levels at 10.1, 80.8, 
or 646.4 ng.mL-1 was kept at room temperature for 24 
hours. The RSD at 0, 2, 6, 12, or 24 h was not more than 
11.1% (LLOQ sample), 1.8%, and 2.1%, respectively.
·	 Stability of plasma diltiazem after freeze-thaw 
circles
The blank plasma with diltiazem levels at 10.1, 80.8, 
or 646.4 ng.mL-1 was frozen at -40 °C and followed three 
freeze-thaw cycles. The RSD was not more than 7.6% 
(LLOQ sample), 3.2%, and 1.7%, respectively.
·	 Stability of plasma diltiazem after frozen storage
The blank plasma with diltiazem levels at 10.1, 80.8, 
or 646.4 ng.mL-1 was analyzed after the samples were fro-
zen at -20 °C for 0 to 28 days. The RSD was not more than 
19.5 % (LLOQ sample), 6.1%, and 4.7%, respectively.
These results showed that the plasma diltiazem was 
quite stable during the whole PK studies.
TABLE II - Precision and accuracy of the analytical method ( 
n = 6)
Concentration 
(ng.mL-1)
Precision (RSD/%)
Intra-day Inner-day
10.1 6.2 7.3
80.8 5.6 3.0
646.4 2.7 4.4
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Pharmacokinetics
Diltiazem was quite well tolerated, in which neither 
serious unexpected events occurred nor drop-out in the 
volunteers during the study. All volunteers were in good 
condition in the clinical trials.
Single dose trial
The mean plasma concentration-time profiles of 36 
healthy volunteers in single oral administration with the 
dose of 90 mg, 180 mg, or 270 mg of diltiazem hydro-
chloride delayed-onset sustained-release pellet capsules 
were shown in Figure 2. The main PK parameters were 
summarized in Table III. Mean Cmax values were 128.26 ± 
22.61, 162.69 ± 32.24, and 191.00 ± 40.26 ng.mL-1. The 
corresponding Tmax values were 11.15 ± 1.10, 11.76 ± 
1.25, and 11.48 ± 1.03 hours, respectively and t1/2β values 
were 14.47 ± 0.42, 14.41 ± 2.32, and 14.89 ± 1.16 hours; 
The Tlag values were 4.85 ± 0.51, 4.81 ± 0.73, 4.58 ± 0.42 
hours. The AUC36 were 2597.97 ± 313.22, 3511.52 ± 
324.90, and 4245.90 ± 468.82 ng.h.mL-1, while the AUC∞ 
were 3131.61 ± 765.71, 4307.71 ± 628.42, and 5341.92 ± 
861.74 ng.h.mL-1 respectively.
Multiple-dose trials
The mean plasma concentration-time profiles of 
multiple oral doses (90 mg) of diltiazem hydrochloride 
delayed-onset sustained-release pellet capsules in 6th day 
were shown in Figure 3. Considering the factual dosing 
interval was 24 h, the PK parameters that were calculated 
by PKSolver 2.0 as Table IV. The mean Cmas,ss value was 
181.33 ± 23.09 ng.mL-1, the corresponding Tmax value was 
10.39 ± 1.32 hour and t1/2β was 14.38 ± 0.72 hour. The Cmin,ss 
was 44.08 ± 3.06 ng.mL-1 and the AUC0~24,ss was 3127.61 ± 
233.37 ng.h.mL-1. The oral clearance (CL/F) of multiple-
dose group was 28775 ± 216 mL.h-1.
TABLE III - Pharmacokinetic parameters of single oral dose (mean ± SD, n = 12)
Parameter
Dose/mg
90 180 270
Tmax/h 11.15 ± 1.10 11.76 ± 1.25 11.48 ± 1.03
Cmax/ng.mL-1 128.26 ± 22.61 162.69 ± 32.24 191.00 ± 40.26
β/h-1 0.0479 ± 0.013 0.0480 ± 0.017 0.0466 ± 0.011
T1/2β /h 14.47 ± 0.42 14.41 ± 2.32 14.89 ± 1.16
Tlag /h 4.85 ± 0.51 4.81 ± 0.73 4.58 ± 0.42
AUC36 /ng.mL.h-1 2597.97 ± 313.22 3511.52 ± 324.90 4245.90 ± 468.82
AUC∞ /ng.mL.h-1 3131.61 ± 765.71 4307.71 ± 628.42 5341.92 ± 861.74
CL/F/mL.h-1 28739 ± 2312 41786 ± 2143 50543 ± 10723
V/F/L 599.979 ± 94.5 870.541 ± 738 1084.613 ± 91.9
TABLE IV - Pharmacokinetic parameters of multiple oral doses 
(mean ± SD, n = 12)
Parameter 90 mg
Tlag/h 4.419 ± 0.012
Tmax/h 10.39 ± 1.32
Cmax,ss/ng.mL-1 181.33 ± 23.09
Cmin,ss/ng.mL-1 44.08 ± 3.06
Css average /ng.mL-1 132.48
β/h-1 0.048 ± 0.027
T1/2β/h 14.38 ± 0.72
AUC0~24,ss/ng.mL.h-1 3127.61 ± 233.37
CL/F/mL.h-1 28775 ± 216
V/F/L 599.499 ± 31.3
DF(degree of fluctuation) 1.06 ± 0.12
FIGURE 2 - Plasma concentration-time curves of single oral 
dose (90,180 or 270 mg) of diltiazem hydrochloride delayed-
onset sustained-release pellet capsules (mean ± SD, n = 12).
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FIGURE 3 - Mean plasma concentration-time profiles of 
multiple oral dose (90mg) of diltiazem hydrochloride delay-
onset sustained-release pellet capsules (6th day) (mean ± SD, 
n = 12).
Food-effects trials
The mean plasma concentration-time profiles of 
high calories food-effects on diltiazem hydrochloride 
delayed-onset sustained-release pellet capsules (360 
mg) and parameters of fasted condition in plasma were 
shown in Figure 4. The corresponding PK parameters 
in steady-state were reported in Table V. The Mean Cmax 
values were 216.09 ± 34.68 and 206.51 ± 41.23 ng.mL-1; 
the corresponding Tmax values were 11.8 ± 1.8 and 11.6 ± 
2.1 hours; the t1/2β were 16.1 ± 4.2 and 14.3 ± 5.7 hours; 
and the AUC36 were 4663.8 ± 1521.3 and 4530.6 ± 1671.2 
ng.h.mL-1, while the AUC∞ were 5851.3 ± 1625.7 and 
5622.9 ± 1756.2 ng.h.mL-1. The oral clearance (CL/F) of 
multiple-dose group from fed and fasted group were 61.5 
± 8.72 and 64.2 ± 1.31 mL.h -1, respectively.
FIGURE 4 - Plasma concentration-time curves of food-effect on 
diltiazem hydrochloride delayed-onset sustained-release pellet 
capsules (4 capsules, 360 mg total) (mean ± SD, n = 12).
DISCUSSION
Several RP-HPLC methods for measuring human 
plasma diltiazem concentration have been reported (Sul-
tana et al., 2010; Zargh et al., 2005). The method that 
sodium hydroxide was used as alkaline extraction solution 
remarkably increased the extraction rates of diltiazem 
from plasma sample (Höglund, Nilsson, 1987). This 
method was simple and sensitive in short analysis time 
for diltiazem determination in plasma. The lower limit 
of quantification (LLOQ) (10.1 ng.mL-1) for the plasma 
diltiazem concentration was suitable for the detection in 
this experiment following the FDA advice (RSD < 20 %).
Compared with the PK parameters obtained from the 
same oral dose of tablets, the main PK parameters of tmax, 
Cmax, AUCt and t1/2 of diltiazem hydrochloride delayed-
onset sustained-release pellet capsules in three single oral 
dose groups were much higher in the present study than 
the corresponding PK parameters reported in the previous 
literatures (Murata et al., 1989; Turner, 2002).
The parameters of AUC36 and AUC∞ in group B with 
the oral administration of 180 mg single dose were higher 
than those in group A with 190 mg, and lower than those 
in group C with 270 mg. The Tlag (about 5 hours) indicted 
that the diltiazem release from the pellets was a delayed 
release character. Moreover, the point deviation in the 
concentration-time curves should be attributed to big 
individual differences among the volunteers.
Theoretically, the main PK parameters obtained 
from single dose and multiple doses are in accordance with 
each other, of which the multiple parameters could be cal-
culated out by single. In this process, the multiple param-
eters of tmax, Cmax,ss, Cmin,ss, Css,average and AUC0~24h,ss calculated 
from single were 5.95 h, 182.24 ng.mL-1, 43.34 ng.mL-1, 
TABLE V - Pharmacokinetic parameters of food-effect on 
delayed-onset sustained-release pellet capsules
Parameter
Dose/360 mg
fasted fed
Tmax/h 11.6 ± 2.1 11.8 ± 1.8
Cmax/ng.mL-1 206.51 ± 41.23 216.09 ± 34.68
β/h-1 0.048 ± 0.021 0.043 ± 0.019
T1/2β/h 14.3 ± 5.7 16.1 ± 4.2
Tlag/h 4.92 ± 0.82 4.80 ± 0.56
AUC36/ng.mL.h-1 4530.6 ± 1671.2 4663.8 ± 1521.3
AUC∞/ng.mL.h-1 5622.9 ± 1756.2 5851.3 ± 1625.7
CL/F/mL.h-1 64.2 ± 1.31 61.5 ± 8.72
Mean ± SD, n = 12; the fasted and fed were the abbreviated of 
fasted food condition and feed condition respectively.
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130.48 ng.mL-1, 3131.61 ng.mL-1 respectively, which 
were well coincided with the corresponding actual values 
listed as Table IV. The only exceptional parameter was 
that the real multiple tmax was 10.39 h, which was thought 
as the total of tlag (4.41 h) and the calculated tmax by single 
(5.95 h). Response to the reported pharmacokinetic pa-
rameters of the same multiple oral dose, the present results 
showed that the time to maximum plasma concentration 
[tmax = (10.39 ± 1.32) h] was prolonged significantly. 
However, the elimination half-life (t1/2β = 14.38 ± 0.72 h) 
remained extending (Lefebvre et al., 1994; Roberts et al., 
1991; Ochs et al., 1984).
A dose of 360 mg diltiazem could be found using in 
clinical practice, thus a dumping dose in high fat food con-
dition effect should be investigated. The comparisons of 
parameters AUC and Cmax after taking delay-onset pellets 
of diltiazem in food and fasted state appeared only slight 
increase (Cmax from 206.51 to 216.09 ng.mL-1; t1/2β from 
14.3 to 16.1 h; AUC∞ from 5622.9 to 5851.3 ng.mL.h-1), 
but the Tmax of fed (11.8±1.8 hour) almost appeared equal 
to that of fasted condition (11.6±2.1 hour). That means the 
delay-onset dosage form was well tolerated under food 
and fast condition. No marked difference was observed in 
the PK parameters and curves. The data showed that the 
delayed-onset dosage form could be administrated without 
regards of food effect.
The diltiazem hydrochloride delayed-onset release 
capsules were mainly used to treat the blood pressure 
and cardiac disease. Indeed, the prominent 24-hour 
variation in the occurrence of a variety of acute cardio-
vascular events, such as myocardial infarction, angina 
pectoris, cardiac arrest and sudden cardiac death have 
been shown to be closely related to the circadian blood 
pressure pattern of hypertensive subjects (Portaluppi et 
al., 1999). The objective of the pellets capsules was to 
adject the diltiazem release to vary with the variation of 
blood pressure in 24-hour time. Such model could match 
the circadian pattern of blood pressure characterized by 
a low span associated with sleep, rest, or inactivity, fol-
lowed by a steep rise over a 4-hour period that occurs 
with awakening and/or arousal and a high span for the 
remainder of the 24-hour period during wakefulness, 
increased activity, or work (White, 1996; Weber et al., 
1988). Therefore, considering the delayed lag time of 
about 5 hours, it suggests that patients take the capsules 
in the bedtime of about 22:00 pm so that the diltiazem 
will release at about 2~3 am and peak blood concentra-
tion appears in morning (Tmax=11.6 h, 360 mg/dose), or 
patients take the capsules at 8:00 am to allow the peak 
drug level between 6:00 and 8:00 pm according to pa-
tient conditions (Hermida et al., 2007). So the diltiazem 
hydrochloride delayed-onset sustained-release pellet 
capsules should be better for the patients to prevent the 
attack of heart disease in sleeping time.
There had a limitation in this study. This study was 
conducted mainly in a small number of young healthy sub-
jects (between 19 and 30 years of age) who did not receive 
additional medications or tobacco. The study population 
cannot be representative population of patients totally 
who might be treated with this medication or with tobacco 
or alcohol. Meanwhile, the drug interactions potentially 
were not assessed, and the influence of co-morbid condi-
tions (e.g. motility disorders, malabsorption disorders and 
achlorhydria) on other aspects of pharmacokinetics could 
not be accounted for either.
CONCLUSIONS
The present study suggested that diltiazem hydro-
chloride delayed-onset sustained-release pellet capsules 
possessed marked characteristics of delayed and controlled 
release. From the PK analysis, the pellets administrated 
showed delayed release time in about 5 hours which will 
comply with the chronopharmacology. The sustained 
release pellets capsules could be orally administrated 
without regard to the food factor.
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